Bystritsky 1995.

Methods	Study design: Randomised controlled trial
Participants	Diagnosis: DSM‐III panic disorder with or without agoraphobia Method of diagnosis: Not stated Age: average age of 37 years, no between‐group differences Sex: 12 males and 9 females, no between‐group differences Location: USA; setting unclear Co‐morbidities: lack of significant drug or alcohol history or significant medical illness; patients that had an additional diagnosis of major depression (MD) or generalised anxiety disorder (GAD) were allowed to participate only if they presented a predominant picture of panic disorder and if panic symptoms preceded the onset of the current episode of MD or GAD Rescue medication: Not stated.
Interventions	Participants were randomly assigned to either: (1) desipramine arm (n = 11) Duration: 10 weeks Treatment Protocol: flexible dosage; range = 10 ‐ 300 mg, M = 110, SD = 49 (2) fluoxetine arm (n = 11) Duration: 10 weeks Treatment Protocol: flexible dosage; range = 2.5 ‐ 60 mg, M = 19, SD = 10
Outcomes	Time points for assessment: weekly Outcomes: 1. Hamilton Rating Scale for Anxiety (HAMA) 2. Hamilton Rating Scales for Depression (HAM‐D) 3. Four Dimensional Anxiety Scale 4. Clinical Global Impression‐Severity of Illness (CGI‐S) 5. Clinical Global Impression‐Improvement (CGI‐I)
Notes	Date of study: Not stated Funding source: this research has been supported in part by NIMH grant MH 45342‐02 and by an NPI Opportunity Grant Declarations of interest among the primary researchers: None.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "they were assigned randomly". No further details.
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Quote: "both patients and investigators were blind to the assignment"; "patients were administered identical capsules labeled A, B or C: Capsules A, containing 2,5 mg of fluoxetine or 10 mg of desipramine were administered for one week [...], capsules B (containing) 25 mg of desipramine or 5 mg of fluoxetine, (capsules) C (containing) 50 mg of desipramine or 10 mg of fluoxetine".
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "both patients and investigators were blind to the assignment"
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	No clear information on incomplete outcome data management.
Selective reporting (reporting bias)	Low risk	All outcomes were reported.
Other bias	Unclear risk	Quote: "this research has been supported in part by NIMH grant MH 45342‐02 and by an NPI Opportunity Grant".